Sara Weymer

Director Técnico/Científico/I+D en BOUNDLESS BIO, INC. .

Health Technology

Perfil

Sara Weymer is currently the Director of Clinical Program Management at ZZ Biotech LLC and the Vice President of Clinical Operations at Boundless Bio, Inc. She previously worked as the Executive Director and Head of Clinical Operations at Fate Therapeutics, Inc.

Cargos activos de Sara Weymer

Empresas	Cargo	Inicio
BOUNDLESS BIO, INC.	Director Técnico/Científico/I+D	04/06/2022
ZZ Biotech LLC ZZ Biotech LLC BiotechnologyHealth Technology ZZ Biotech LLC operates as a clinical stage company. It develops biologic treatments for ischemic stroke and other neurological diseases and wound healing applications including the treatment of diabetic foot ulcers. The firm mainly focuses on developing 3K3A-APC, a novel second-generation variant of a naturally occurring human protein licensed from The Scripps Research Institute. The company was founded by Selim Zilkha and Berislav V. Zlokovic in 2006 and is headquartered in Houston, TX.	Corporate Officer/Principal	-

Todos los cargos activos de Sara Weymer

Antiguos cargos conocidos de Sara Weymer.

Empresas	Cargo	Fin
FATE THERAPEUTICS, INC.	Director/Miembro de la Junta	-

Ver el detalle de la experiencia de Sara Weymer.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Sara Weymer.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	2
BOUNDLESS BIO, INC.	Health Technology
FATE THERAPEUTICS, INC.	Health Technology

Empresas privadas	1
ZZ Biotech LLC ZZ Biotech LLC BiotechnologyHealth Technology ZZ Biotech LLC operates as a clinical stage company. It develops biologic treatments for ischemic stroke and other neurological diseases and wound healing applications including the treatment of diabetic foot ulcers. The firm mainly focuses on developing 3K3A-APC, a novel second-generation variant of a naturally occurring human protein licensed from The Scripps Research Institute. The company was founded by Selim Zilkha and Berislav V. Zlokovic in 2006 and is headquartered in Houston, TX.	Health Technology